Martin L, Anguita A, Graf N, Tsiknakis M, Brochhausen M, Rüping S, Bucur A, Sfakianakis S, Sengstag T, Buffa F, Stenzhorn H

ACGT: advancing clinico-genomic trials on cancer - four years of experience.

Stud Health Technol Inform 2011; 734-8.

Mehta S, Hughes NP, Buffa FM, Li SP, Adams RF, Adwani A, Taylor NJ, Levitt NC, Padhani AR, Makris A, Harris AL

Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles.

J Natl Cancer Inst Monogr 2011; 71-4. doi: 10.1093/jncimonographs/lgr027

Piccaluga PP, Agostinelli C, Gazzola A, Tripodo C, Bacci F, Sabattini E, Sista MT, Mannu C, Sapienza MR, Rossi M, Laginestra MA, Sagramoso-Sacchetti CA, Righi S, Pileri SA

Pathobiology of hodgkin lymphoma.

Adv Hematol 2011; 920898. doi: 10.1155/2011/920898

Visani G, Sapienza MR, Isidori A, Tripodo C, Laginestra MA, Righi S, Sagramoso Sacchetti CA, Gazzola A, Mannu C, Rossi M, De Nictolis M, Valentini M, Donati M, Emiliani R, Alesiani F, Paolini S, Finelli C, Pileri SA, Piccaluga PP

SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis.

PLoS One 2011; e27560. doi: 10.1371/journal.pone.0027560

Avila RL, D'Antonio M, Bachi A, Inouye H, Feltri ML, Wrabetz L, Kirschner DA

P0 (protein zero) mutation S34C underlies instability of internodal myelin in S63C mice.

J Biol Chem 2010; 42001-12. doi: 10.1074/jbc.M110.166967

Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Håkansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll H, Siena S, Tabernero J, Van Cutsem E

Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.

Curr Opin Mol Ther 2010; 703-11.

Mosca L, Fabris S, Lionetti M, Todoerti K, Agnelli L, Morabito F, Cutrona G, Andronache A, Matis S, Ferrari F, Gentile M, Spriano M, Callea V, Festini G, Molica S, Deliliers GL, Bicciato S, Ferrarini M, Neri A

Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion.

Clin Cancer Res 2010; 5641-53. doi: 10.1158/1078-0432.CCR-10-0151

Pierobon P, Miné-Hattab J, Cappello G, Viovy JL, Lagomarsino MC

Separation of time scales in one-dimensional directed nucleation-growth processes.

Phys Rev E Stat Nonlin Soft Matter Phys 2010; 061904. doi: 10.1103/PhysRevE.82.061904

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

BMC Cancer 2010; 631. doi: 10.1186/1471-2407-10-631

Magli A, Angelelli C, Ganassi M, Baruffaldi F, Matafora V, Battini R, Bachi A, Messina G, Rustighi A, Del Sal G, Ferrari S, Molinari S

Proline isomerase Pin1 represses terminal differentiation and myocyte enhancer factor 2C function in skeletal muscle cells.

J Biol Chem 2010; 34518-27. doi: 10.1074/jbc.M110.104133

Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, Fazi C, Muzio M, Caiolfa V, Kitamura D, Restuccia U, Bachi A, Rocchi M, Ponzoni M, Ghia P, Caligaris-Cappio F

HS1 has a central role in the trafficking and homing of leukemic B cells.

Blood 2010; 3537-46. doi: 10.1182/blood-2009-12-258814

Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

Cancer Treat Rev 2010; S1-5. doi: 10.1016/S0305-7372(10)70012-8

Grassi L, Fusco D, Sellerio A, Corà D, Bassetti B, Caselle M, Lagomarsino MC

Identity and divergence of protein domain architectures after the yeast whole-genome duplication event.

Mol Biosyst 2010; 2305-15. doi: 10.1039/c003507f

Marín GH, Mansilla E, Mezzaroba N, Zorzet S, Núñez L, Larsen G, Tau JM, Maceira A, Spretz R, Mertz C, Ingrao S, Tripodo C, Tedesco F, Macor P

Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.

Curr Clin Pharmacol 2010; 246-50. doi: 10.2174/157488410793352058

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

JAMA 2010; 1812-20. doi: 10.1001/jama.2010.1535

Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

J Clin Oncol 2010; 4554-61. doi: 10.1200/JCO.2009.27.5867

Piconese S, Pittoni P, Burocchi A, Gorzanelli A, Carè A, Tripodo C, Colombo MP

A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2.

Eur J Immunol 2010; 2902-13. doi: 10.1002/eji.201040505

Agostinis C, Bulla R, Tripodo C, Gismondi A, Stabile H, Bossi F, Guarnotta C, Garlanda C, De Seta F, Spessotto P, Santoni A, Ghebrehiwet B, Girardi G, Tedesco F

An alternative role of C1q in cell migration and tissue remodeling: contribution to trophoblast invasion and placental development.

J Immunol 2010; 4420-9. doi: 10.4049/jimmunol.0903215

Floriani I, Garassino MC, Broggini M, Veronese S, Marsoni S, Marabese M, Farina G, Scanni A

Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?

J Clin Oncol 2010; e467; author reply e468. doi: 10.1200/JCO.2010.28.5973

Liu F, Dangaria S, Andl T, Zhang Y, Wright AC, Damek-Poprawa M, Piccolo S, Nagy A, Taketo MM, Diekwisch TG, Akintoye SO, Millar SE

beta-Catenin initiates tooth neogenesis in adult rodent incisors.

J Dent Res 2010; 909-14. doi: 10.1177/0022034510370090

Fachinetti D, Bermejo R, Cocito A, Minardi S, Katou Y, Kanoh Y, Shirahige K, Azvolinsky A, Zakian VA, Foiani M

Replication termination at eukaryotic chromosomes is mediated by Top2 and occurs at genomic loci containing pausing elements.

Mol Cell 2010; 595-605. doi: 10.1016/j.molcel.2010.07.024

Fardin MA, Rossier OM, Rangamani P, Avigan PD, Gauthier NC, Vonnegut W, Mathur A, Hone J, Iyengar R, Sheetz MP

Cell spreading as a hydrodynamic process.

Soft Matter 2010; 4788-4799. doi: 10.1039/c0sm00252

Rzymski T, Milani M, Pike L, Buffa F, Mellor HR, Winchester L, Pires I, Hammond E, Ragoussis I, Harris AL

Regulation of autophagy by ATF4 in response to severe hypoxia.

Oncogene 2010; 4424-35. doi: 10.1038/onc.2010.191

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Lancet Oncol 2010; 753-62. doi: 10.1016/S1470-2045(10)70130-3

Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.

J Clin Invest 2010; 2858-66. doi: 10.1172/JCI37539

Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

J Clin Invest 2010; 2842-57. doi: 10.1172/JCI36125

Morsut L, Yan KP, Enzo E, Aragona M, Soligo SM, Wendling O, Mark M, Khetchoumian K, Bressan G, Chambon P, Dupont S, Losson R, Piccolo S

Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo.

Development 2010; 2571-8. doi: 10.1242/dev.053801

Tripodo C, Gri G, Piccaluga PP, Frossi B, Guarnotta C, Piconese S, Franco G, Vetri V, Pucillo CE, Florena AM, Colombo MP, Pileri SA

Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma.

Am J Pathol 2010; 792-802. doi: 10.2353/ajpath.2010.091286

Maffei R, Martinelli S, Santachiara R, Rossi D, Guarnotta C, Sozzi E, Zucchetto A, Rigolin GM, Fiorcari S, Castelli I, Fontana M, Coluccio V, Leonardi G, Zucchini P, Tripodo C, Cuneo A, Gattei V, Del Poeta G, Forconi F, Gaidano G, Torelli G, Marasca R

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

Blood 2010; 584-92. doi: 10.1182/blood-2009-11-252494

Manzoni R, Montani F, Visintin C, Caudron F, Ciliberto A, Visintin R

Oscillations in Cdc14 release and sequestration reveal a circuit underlying mitotic exit.

J Cell Biol 2010; 209-22. doi: 10.1083/jcb.201002026

Mantovani F, Drost J, Voorhoeve PM, Del Sal G, Agami R

Gene regulation and tumor suppression by the bromodomain-containing protein BRD7.

Cell Cycle 2010; 2777-81.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

J Clin Oncol 2010; 3219-26. doi: 10.1200/JCO.2009.27.1825

%PLACEHOLDER%